


**WHAT IS CLAIMED IS:**

- 1 A3 SVA 1. A composition for the treatment of proliferative disorders,  
2 comprising an antineoplastic agent and a compound having the formula:



- 3  
4 and pharmaceutically acceptable salts thereof;  
5 wherein

6 R is a member selected from the group consisting of hydrogen and  
7 substituted or unsubstituted (C<sub>1</sub>-C<sub>10</sub>)alkyl; and

8 Ar is a member selected from the group consisting of substituted or  
9 unsubstituted aryl and substituted or unsubstituted heteroary

- 1  
2 2. A composition in accordance with claim 1, wherein said  
3 antineoplastic agent is selected from the group consisting of DNA-alkylating agents,  
4 antimetabolites, antifolates and other inhibitors of DNA synthesis, microtubule disruptors,  
5 DNA intercalators, hormone agents, topoisomerase I/II inhibitors, DNA repair agents,  
6 growth factor receptor kinase inhibitors, biological response modifiers, antiangiogenic  
and antivascular agents, immunoconjugates and antisense oligonucleotides.

- 1  
2 3. A composition in accordance with claim 1, wherein said  
3 antineoplastic agent is selected from the group consisting of cyclophosphamide, BCNU,  
4 busulfan, temozolomide, UFT, capecitabine, gemcitabine, cytarabine, imrosulfan,  
5 piposulfan, benzodepa, carboquone, meturedopa, uredepa, altretamine,  
6 triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide,  
7 trimethylolmelamine, chlorambucil, estramustine, ifosfamide, novembrichin,  
8 prednimustine, uracil mustard, dacarbazine, fluorouracil, methotrexate, mercaptoperine,  
9 thioguanine, vinblastine, vincristine, vinorelbine, vindesine, etoposide, teniposide,  
10 daunorubicin, doxorubicin, epirubicin, mitomycin, dactinomycin, daunomycin,  
11 plicamycin, bleomycin, L-asparaginase, camptothecin, hydroxyurea, procarbazine,  
12 mitotane, aminoglutethimide, tamoxifen, flutamide, mitoxantrone, paclitaxel, docetaxol,  
and thiotepa.

13           4. A composition in accordance with claim 1, wherein said  
14 antineoplastic agent is selected from the group consisting of doxorubicin, daunorubicin,  
15 gemcitabine and paclitaxel.


16           5. A composition in accordance with claim 1, wherein said  
17 antineoplastic agent is gemcitabine or paclitaxel.

1           6. A composition in accordance with claim 1, wherein R is hydrogen  
2 or unsubstituted (C<sub>1</sub>-C<sub>4</sub>)alkyl.


1           7. A composition in accordance with claim 1, wherein Ar is a  
2 substituted phenyl group.

1           8. A composition in accordance with claim 7, wherein said  
2 substituents on said phenyl group are selected from the group consisting of halogen, (C<sub>1</sub>-  
3 C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, -OPO<sub>3</sub>H<sub>2</sub>,

1           9. A composition in accordance with claim 8, wherein Ar represents a  
2 member selected from the group consisting of




1                    10. A composition in accordance with claim 1, wherein said compound  
2 is selected from the group consisting of:



1           **11.** A method for the treatment of a proliferative disorder, comprising  
2 administering to a subject in need of such treatment an effective amount of a composition  
3 of claim 1.

1           **12.** A. method in accordance with claim 11, wherein said compound is  
2 selected from the group consisting of:

3



4           **13.** A method in accordance with claim 12, wherein said antineoplastic  
5 agent is selected from the group consisting of DNA-alkylating agents, antimetabolites,  
6 antifolates and other inhibitors of DNA synthesis, microtubule disruptors, DNA  
7 intercalators, hormone agents, topoisomerase I/II inhibitors, DNA repair agents, growth  
8 factor receptor kinase inhibitors, biological response modifiers, antiangiogenic and  
9 antivascular agents, immunoconjugates and antisense oligonucleotides.

1           **14.** A method in accordance with claim 12, wherein said antineoplastic  
2 agent is selected from the group consisting of cyclophosphamide, BCNU, busulfan,  
3 temozolamide, UFT, capecitabine, gemcitabine, cytarabine, imrosulfan, piposulfan,  
4 benzodepa, carboquone, meturedopa, uredepa, altretamine, triethylenemelamine,  
5 triethylenephosphoramide, triethylenethiophosphoramide, trimethylolmelamine,  
6 chlorambucil, estramustine, ifosfamide, novembrichin, prednimustine, uracil mustard,  
7 dacarbazine, fluorouracil, methotrexate, mercaptapurine, thioguanine, vinblastine,


8 vincristine, vinorelbine, vindesine, etoposide, teniposide, daunorubicin, doxorubicin,  
9 epirubicin, mitomycin, dactinomycin, daunomycin, plicamycin, bleomycin, L-  
10 asparaginase, camptothecin, hydroxyurea, procarbazine, mitotane, aminoglutethimide,  
11 tamoxifen, flutamide, mitoxantrone, paclitaxel, docetaxol, and thiotepa.

12        15. A method in accordance with claim 12, wherein said antineoplastic  
13 agent is selected from the group consisting of doxorubicin, daunorubicin, gemcitabine  
14 and paclitaxel.

15        16. A method in accordance with claim 12, wherein said antineoplastic  
16 agent is gemcitabine or paclitaxel.

17 *A5 SCH* 17. A method for the treatment of a proliferative disorder, comprising  
18 administering to a subject in need of such treatment:

- 19            i) a first amount of an antineoplastic agent; and  
20            ii) a second amount of a compound of formula:




21  
22 and pharmaceutically acceptable salts thereof; wherein

23            R is a member selected from the group consisting of hydrogen and  
24 substituted or unsubstituted (C<sub>1</sub>-C<sub>10</sub>)alkyl; and


25            Ar is a member selected from the group consisting of substituted or  
26 unsubstituted aryl and substituted or unsubstituted heteroaryl;

27            wherein said first amount and said second amount, in combination, are  
28 effective to treat said proliferative disorder

1        18. A method in accordance with claim 17, wherein said compound is  
2 selected from the group consisting of



and



3

4

5           **19.** A method in accordance with claim 18, wherein said antineoplastic  
 6 agent is selected from the group consisting of DNA-alkylating agents, antimetabolites,  
 7 antifolates and other inhibitors of DNA synthesis, microtubule disruptors, DNA  
 8 intercalators, hormone agents, topoisomerase I/II inhibitors, DNA repair agents, growth  
 9 factor receptor kinase inhibitors, biological response modifiers, antiangiogenic and  
 10 antivascular agents, immunoconjugates and antisense oligonucleotides.

1           **20.** A method in accordance with claim 18, wherein said antineoplastic  
 2 agent is selected from the group consisting of cyclophosphamide, BCNU, busulfan,  
 3 temozolomide, UFT, capecitabine, gemcitabine, cytarabine, imrosulfan, piposulfan,  
 4 benzodepa, carboquone, meturedopa, uredepa, altretamine, triethylenemelamine,  
 5 triethylenephosphoramide, triethylenethiophosphoramide, trimethylolmelamine,  
 6 chlorambucil, estramustine, ifosfamide, novembrichin, prednimustine, uracil mustard,  
 7 dacarbazine, fluorouracil, methotrexate, mercaptopurine, thioguanine, vinblastine,  
 8 vincristine, vinorelbine, vindesine, etoposide, teniposide, daunorubicin, doxorubicin,  
 9 epirubicin, mitomycin, dactinomycin, daunomycin, plicamycin, bleomycin, L-  
 10 asparaginase, camptothecin, hydroxyurea, procarbazine, mitotane, aminoglutethimide,  
 11 tamoxifen, flutamide, mitoxantrone, paclitaxel, docetaxol, and thiotepa.

12           **21.** A method in accordance with claim 18, wherein said antineoplastic  
 13 agent is selected from the group consisting of doxorubicin, daunorubicin, gemcitabine  
 14 and paclitaxel.

15                   **22.**     A method in accordance with claim 18, wherein said antineoplastic  
16     agent is gemcitabine or paclitaxel.

17

18                   **23.** A method in accordance with claim 18, wherein said antineoplastic  
19 agent is administered prior to said compound.

20

21                   **24.** A method in accordance with claim 18, wherein said antineoplastic  
22 agent is administered after said compound.

23

24                   **25.** A method in accordance with claim 18, wherein said antineoplastic  
25 agent is administered simultaneously with said compound.

三〇〇